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Introduction
The resistance of Gram-negative rods to antibacterial 
compounds is related to the occurrence and interaction 
of several independent mechanisms of resistance. The 
following resistance mechanisms have been described 
in these rods: the production of various enzymes that 
inactivate antibiotics (e.g. β-lactams, aminoglycosides), 
active extrusion of bacterial compounds by membrane 
pumps (that govern resistance to fluoroquinolones, but 
the contribution of efflux pumps to β-lactams and tetra-
cycline resistance has also been described), changes in 
the target sites of chemotherapeutic agents (e.g. fluo-
roquinolones, tetracyclines), alterations in outer mem-
brane permeability that perturb the influx of antibiot-
ics (e.g. some β-lactams), or involvement of additional 
metabolic pathways (primarily related to resistance 
to cotrimoxazole). Currently, the greatest therapeutic 
challenge is treatment of infections caused by Gram-
negative rods producing β-lactam hydrolysing enzymes, 
i.e. metallo-β-lactamases (MBL), carbapenemases KPC-
type (Klebsiella pneumoniae carbapenemases) and 
extended-spectrum β-lactamases (ESBL) (Miriagou 
et al., 2010; Poirel et al., 2012). However, the underes-
timated resistance mechanism of Gram-negative rods 
is an overexpression of multi-drug resistance (MDR) 
efflux pumps. In these rods the efflux pumps from 
all known five families are present, as follows: ABC 
(ATP-binding cassette family), RND (resistance-nod-
ulation-division family), MFS (major facilitator super-
family), SMR (small multidrug resistance family), and 
MATE (multidrug and toxic compound extrusion fam-
ily) (Piddock, 2006; Nikaido and Pages, 2012). The main 
role in resistance of rods plays the RND efflux systems 
that can simultaneously remove several different classes 
of antibiotics, biocides as well as organic compounds 
from bacterial cells. The RND proteins are encoded by 
genes organized in operons that are located in bacterial 
chromosomes (Piddock, 2006). Two new efflux pumps 
– OqxAB and QepA, encoded by genes located in conju-
gational plasmids, have recently been reported (Yamane 
et al., 2008; Kim et al., 2009). Expression of genes encod-
ing efflux pumps as well as the efflux systems operons 
are regulated by both local and global regulator genes 
(Grkovic et al., 2002; Piddock, 2006). In Gram-negative 
rods from the Enterobacteriaceae family, four groups of 
proteins (e.g. Mar, Sox, Rob and Ram) play role as global 
regulators of pump-encoding genes. The most important 
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A b s t r a c t
Non-antibiotic medicinal products consist of drugs with diverse activity against bacteria. Many non-antibiotics demonstrate direct anti-
bacterial activity against Gram-positive cocci. The activity observed against Gram-negative rods is much lower and non-antibiotics primarily 
from the following groups: non-steroidal anti-inflammatory drugs, cardiovascular and antidepressant medicinal products demonstrate this 
activity. It has been shown that the low activity of some non-antibiotics or the absence of activity against Gram-negative rods is related, 
among other things, to the extrusion of these compounds from bacterial cells by multi-drug resistance efflux pumps. Substrates for the 
resistance-nodulation-division efflux systems include the following non-antibiotics: salicylate, diclofenac, ibuprofen, mefenamic acid, 
naproxen, amitriptyline, alendronate sodium, nicergoline, and ticlopidine. In addition, interactions between non-antibiotics and multi-drug 
resistance efflux pumps have been observed. It has also been revealed that depending on the concentration, salicylate induces expression of 
multi-drug resistance efflux pumps in Escherichia coli, Salmonella enterica subsp. enterica serotype Typhimurium, and Burkholderia cenoce­
pacia. However, salicylate does not affect the expression of the resistance-nodulation-division efflux systems in Stenotrophomonas maltophilia 
and Acinetobacter baumannii. Most importantly, there were no effects of medicinal products containing some non-antibiotic active substances, 
except salicylate, as substrates of multi-drug resistance efflux pumps, on the induction of Gram-negative rod resistance to quinolones.
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global regulator in Pseudomonas aeruginosa (non-
fermentative Gram-negative rods) is the SoxR protein.
In bacteria, the presence of various resistance 
mechanisms, their interactions, and their complicity in 
conditioning the resistance of strains to antimicrobial 
compounds has resulted in increased difficulty in the 
treatment of infections as well as less effective treat-
ment. The World Health Organization (WHO) in Feb-
ruary 2017 published a list of the most dangerous bac-
terial pathogens, divided into 12 groups, which should 
be the priority of current research and new therapeutic 
options (WHO, 2017). The first group of these “criti-
cal” bacteria contains Gram-negative rods: Acinetobac­
ter baumannii, P. aeruginosa, and Enterobacteriaceae, 
which exhibit resistance to carbapenems. In addition, 
this group also includes Enterobacteriaceae strains, 
which produce ESBL enzymes. The WHO predicts that 
in the near future there may be a rapid increase in the 
number of infections caused by these rods, for which we 
no longer have effective therapeutic options. Therefore, 
the urgent challenge is to identify new groups of com-
pounds with potential broad spectrum antimicrobial 
activity, especially against Gram-negative rods, which 
have recently been shown to be responsible for many 
life-threatening infections. For many years, research has 
been conducted to devise new therapeutic approaches 
for the treatment of bacterial infections, such as the 
manipulation of the host microbiome and the use of 
bacteriophages to kill bacteria.
An alternative to the search for new therapeutic 
options is the examination of so-called “non-antibio-
tics, which include medicines from various therapeu-
tic groups used to treat diseases not related to micro-
bial infections. The active substances of these drugs 
may also possess antibacterial activity (Martins et al., 
2008). However, most of the tested non-antibiotics have 
been shown to exhibit direct activity only against 
Gram-positive cocci. Considering the wide substrate 
range of RND efflux systems in Gram-negative bacteria 
(Laudy, 2008; Nikaido and Pages, 2012; Li et al., 2015), 
the contribution of these pumps to the rods resistance 
to non-antibiotics was investigated (Laudy et al., 2016; 
2017). It is known that the reduction of susceptibility 
of Gram-negative rods to many antibiotics and disin-
fectants is due to the fact that they are substrates for 
MDR efflux pumps (Laudy, 2008; Nikaido and Pages, 
2012; Li et al., 2015).
Direct antibacterial activity of non-antibiotics
The group of non-antibiotic drugs may be divided 
into two subgroups, which differ in biological activ-
ity. The first subgroup consists of so-called antimicro-
bial non-antibiotics, which possess direct antibacterial 
activity. The second subgroup consists of two sub-
classes: the “helper compounds”, which alter the perme-
ability of bacteria to conventional antibiotics, and the 
“macrophage modulators”, which enhance the cytotoxic 
activity of macrophages involved in bacterial phago-
cytosis (Martins et al., 2008).
Most of the data published thus far relates to the 
direct antibacterial activity of non-antibiotics. However, 
it should be noted that the minimal inhibitory concen-
tration (MIC) values of non-antibiotics against bacteria 
were not always determined in accordance with Clini-
cal Laboratory Standard Institute (CLSI) recommenda-
tions and therefore some of these results may not be 
fully comparable. In addition, the studies were often 
conducted with only active substances of non-anti-
biotics and less frequently with the relevant medicinal 
products. The compounds tested belonged to various 
therapeutic groups, including anti-inflammatory drugs, 
cardiovascular drugs, antianaplastics, antiarrhythmics, 
anticonvulsants, antidepressants, antihypertensives, 
and spasmolytics. However, most of these non-anti-
biotic agents showed only marginal direct antibacte-
rial activity (MIC ≥ 3000 mg/l) (Kruszewska et al., 2008; 
2010; Laudy et al., 2016; 2017). Some of these com-
pounds e.g. most phenothiazines (Kristiansen et al., 
2007), some antihistamines (Kruszewska et al., 2002), 
anaesthetics (Kruszewska et al., 2002), dodecyl(C(12))
gallate(3,4,5-trihydroxybenzoate) (Kubo et al., 2003), 
and trans-chlorprothixene (Kristiansen et al., 2010) 
were active only against Gram-positive cocci. How-
ever, for a  few non-antibiotics a significant activity 
(MIC ≤ 800 mg/l) against both Gram-positive and 
Gram-negative bacteria has been described. These 
compounds include some phenothiazines (proma-
zine (Hendricks et al., 2003) and chloropromazine 
(Kristiansen et al., 2010)), some cardiovascular drugs 
(Mazudar et al., 2010), 2-dimethyl-amino-ethylchloride 
(Hendricks et al., 2003), oxymetazoline (Kruszewska 
et al., 2002), and sertraline (Kruszewska et al., 2004).
The activity against Gram-negative rods of non-
antibiotic active substances from the following groups: 
local anesthetics (e.g. lidocaine, bupivacaine, and 
ropivacaine) against Escherichia coli and P. aeruginosa 
(Tamanai-Shacoori et al., 2007); locally vasoconstrictive 
agents (e.g. oxymetazoline) against E. coli (Kruszewska 
et al., 2002), and proton pump inhibitors (e.g. rabe-
prazole and lansoprazole) against Helicobacter pylori 
(Bown, 2002) has also been reported. However, most 
compounds of the non-antibiotics group show only low 
activity against Gram-negative rods, i.e., MIC values 
> 3000 mg/l (Kruszewska et al., 2010).
Cardiovascular drugs are the group of non-anti bio-
tics, to which special attention should be paid. Some 
of these drugs display high activity not only against 
Gram-positive cocci (e.g. Staphylococcus aureus), but 
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also against Enterobacteriaceae and non-fermentative 
Gram-negative rods (Mazumdar et al., 2010). The high-
est activity (MICs of 10–200 mg/l) was demonstrated 
for the cardiovascular agents amlodipine, dobutamine, 
lacidipine, nifedipine, and oxyfedrine against the follow-
ing Gram-negative bacteria: E. coli (2–25 strains were 
used in these studies), Klebsiella sp. (3–8 strains), Sal­
monella sp. (5–14 strains), Shigella sp. (12–42 strains), 
and Pseudomonas sp. (1–8  strains). In addition, the 
effects of these five cardiovascular agents in combina-
tion with various antibiotics against Gram-negative 
rods were analysed using in vitro tests, including the 
disc diffusion method, the checkerboard assay, and 
evaluation of the fractional inhibitory concentration 
(FIC) index. The synergism between tetracycline and 
oxyfedrine (FIC index 0.15) (Mazumdar et al., 2005), 
and streptomycin and amlodipine (FIC index 0.28) 
(Asok et al., 2004), was demonstrated against Shigella 
dysenteriae 7 NCTC 519/66. In another study, lacidipine 
showed synergism only with triflupromazine against 
Salmomella enterica subsp. enterica serotype Typhimu-
rium NCTC 74 (Dasgupta et al., 2010). However, these 
studies were conducted only on active substances of 
cardiovascular drugs.
The important observation has been published 
recently (Laudy et al., 2017). The antidepressant agent 
amitriptyline and the relevant medicinal product 
(Amitriptylinum tabl.) have been shown to be active, 
with MIC values ranging from 100 to 800 mg/l, against 
all 180 studied clinical strains from species such as 
K. pneumoniae, E. coli, P. aeruginosa, A. baumannii, and 
Stenotrophomonas maltophilia. Moreover, in this study 
all clinical strains of P. aeruginosa and S. maltophilia 
were also susceptible (MICs ≤ 800 mg/l) to alendronate 
sodium, a specific inhibitor of osteoclast-mediated 
bone resorption, and the relevant medicinal product 
(Ostenil tabl.). It is worth emphasising that the MIC 
values of alendronate were ≤ 200 mg/l for 33/36 P. aeru­
ginosa and 10/36 S. maltophilia strains studied.
More interesting non-antibiotics with potential 
antibacterial activity are the non-steroidal anti-inflam-
matory drugs (NSAIDs), which are among the most 
commonly and most widely used drugs in the world. 
The NSAID group includes compounds with different 
chemical structures; however, all of them show, in vary-
ing degrees, three biological activities: anti-inflamma-
tory, analgesic, and antipyretic. The best-known sub-
stance in this group is diclofenac. The activity of the 
active substance diclofenac against the broad spectrum 
of Gram-negative rods, including E. coli, Klebsiella sp., 
Salmonella sp., Shigella sp., and Vibrio cholerae, has been 
described (Mazumdar et al., 2006; Dutta et al., 2007). In 
addition, the activity of diclofenac, both as an active 
substance alone and as a medicinal product containing 
diclofenac (Olfen tabl. and Diclac ini.), against all tested 
clinical strains of K. pneumoniae, E. coli, Proteus mira bi­
lis, P. aeruginosa, A. baumannii, and S. maltophilia, with 
MIC values ranging from 800 to 3200 mg/l, has been 
demonstrated (Laudy et al., 2016). Furthermore, it has 
been shown that diclofenac inhibits bacterial DNA syn-
thesis (Dastidar et al., 2000). Recently, the mechanism 
of action of the other small molecules of the NSAID 
group, including bromfenac, carprofen, and vedapro-
fen, has been demonstrated (Yin et al., 2014). These 
compounds inhibited the E. coli DNA polymerase III b 
subunit, which disturbed DNA replication. Targeting 
the bacterial DNA replication machinery is a validated 
strategy for production of antibacterial chemotherapeu-
tics like quinolones. In contrast to the fluoroquinolones, 
the NSAIDs that inhibit DNA replication exhibit weak 
antibacterial activity (Yin et al., 2014).
Among the NSAIDs, the activity of acetylsalicylic 
acid against E. coli (Al-Bakri et al., 2009; Laudy et al., 
2016), P. aeruginosa, S. maltophilia, A. baumannii (Laudy 
et al., 2016), and H. pylori (Wang et al., 2003) was also 
demonstrated. Furthermore, H. pylori demonstrated 
the increased sensitivity to antibiotics in the presence 
of acetylsalicylic acid (Wang et al., 2003). The activity 
of ibuprofen and indometacin against H. pylori has also 
been demonstrated (Shirin et al., 2006). More over, the 
activities of ibuprofen/Nurofen tabl. and naproxen/
Naproxen tabl., as well as the active substances and 
medical products containing these agents against clini-
cal strains of S. maltophilia (MICs 800–3200 mg/l) have 
been described (Laudy et al., 2016).
Non-antibiotics as substrates of MDR efflux pumps
The cellular envelopes of Gram-negative rods con-
tain MDR efflux pumps, which actively extrude harm-
ful substances, such as antibiotics, chemotherapeutics, 
and disinfectants from bacteria. In contrast to pumps 
present in Gram-positive bacteria, MDR efflux pumps 
of Gram-negative rods extrude compounds of simi-
lar structures as well as several groups of substances 
that differ significantly from one another. The main 
role in the resistance of rods to antibiotics is played 
by the RND efflux systems, which exhibit wide sub-
strate specificity (Laudy, 2008; Nikaido et al., 2012; 
Li et al., 2015). These systems, unlike the other MDR 
efflux pumps, have a wide substrate spectrum and can 
extrude many different antibacterial chemical com-
pounds, such as antibiotics (mainly quinolones, tetra-
cyclines, aminoglycosides, β-lactams, chloramphenicol, 
and erythro mycin), disinfecting agents (e.g. triclosan), 
some aromatic hydrocarbons, acriflavine, rhodamine 
6G, vanadium, crystal violet, and ethidium bromide. 
The best-known MDR efflux systems are MexAB-OprM 
(found in P. aeruginosa) and AcrAB-TolC (originally 
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described in E. coli, but also found in other species of 
the Enterobacteriaceae family) (Laudy, 2008; Nikaido 
et al., 2012; Li et al., 2015). Moreover, it has been shown 
that an overexpression of pump systems from the 
RND family causes resistance or reduced sensitivity of 
clinical strains, e.g. P. aeruginosa to fluoroquinolones 
(Kriengkauykiat et al., 2005; Adabi et al., 2015).
Considering the wide and diverse substrates range 
of the RND efflux systems, a study was conducted on 
the influence of MDR efflux pumps on the activity of 
non-antibiotics, both active substances and the corre-
sponding drugs, against Gram-negative bacteria (Laudy 
et al., 2016; 2017). Such a phenomenon was fully docu-
mented for salicylate, an essential NSAID belonging 
to non-antibiotics, which is a substrate of the CeoAB-
OpcM efflux system in Burkholderia cenocepacia (Nair 
et al., 2004). The increased accumulation of radiola-
beled salicylate after the addition of 0.25 mM of the 
proton conductor, carbonyl cyanide m-chlorophenyl-
hydrazone (CCCP), was observed. In the presence of 
CCCP, the bacterial cell membrane was de-energised. 
Furthermore, it was also observed that other NSAIDs, 
both active substances and relevant medicinal prod-
ucts, such as mefenamic acid/Mefacit tabl., ibuprofen/
Nurofen tabl., naproxen/Naproxen tabl., diclofenac/
Olfen tabl., and Diclac ini., were actively removed, most 
likely by MDR efflux pumps present in Enterobacte­
riaceae and in non-fermentative Gram-negative rods 
(Laudy et al., 2016). This research was carried out by 
phenotypic methods using Phe-Arg-β-naphthylamide 
(PAβN), an inhibitor of efflux pumps that belongs to 
the RND family (Lomovskaya et al., 2001). It is known 
that PAβN potently inhibits efflux systems of the Mex 
family in P. aeruginosa (especially MexAB-OprM) and 
inhibits the AcrAB-TolC efflux system of the Enterobac­
teriaceae family (e.g. E. coli, K. pneumoniae, P. mirabilis, 
Enterobacter aerogenes, and S. enterica subsp. enterica 
serotype Typhimurium) (Lomovskaya et al., 2001; Pagès 
and Amaral, 2009; Nikaido et al., 2012; Li et al., 2015). 
An in vitro phenotypic screening of bacteria for anti-
biotic removal by MDR efflux pumps is based on meas-
urement of changes in the MICs values of antibiotic 
in the absence or presence of the efflux pump inhibi-
tor (Lomovskaya et al., 2001; Kriengkauykiat et al., 
2005; Adabi et al., 2015; Laudy et al., 2015). Signi-
ficant decreases (≥ 4-fold) in the MIC values of the 
NSAID non-antibiotics: mefenamic acid/Mefacit tabl., 
ibuprofen/Nurofen tabl., naproxen/Naproxen tabl., 
diclofenac/Olfen tabl., and Diclac ini. in the presence 
of PAβN was demonstrated among majority of clinical 
strains of K. pneumoniae, E. coli, P. mirabilis, P. aeru­
ginosa, A. baumannii, and S. maltophilia (Laudy et al., 
2016). In the presence of PAβN, the highest increase 
in bacterial susceptibility to NSAIDs was observed for 
diclofenac and mefenamic acid and the relevant medici-
nal products when the isolates of S. maltophilia (MICs 
of 25–1000 and 100 mg/l, respectively) and E. coli 
(MICs of 50 and 100 mg/l, respectively) were studied. 
In addition, significant increases in the susceptibility of 
E. coli and P. mirabilis clinical strains to acetylsalicylic 
acid/Aspirin tabl. were shown in the presence of PAβN 
(Laudy et al., 2016).
The research was also conducted with non-antibi-
otics from other non-NSAIDs therapeutic groups. The 
impact of PAβN on the susceptibility of bacteria to 
active substances and the relevant medicinal pro ducts, 
such as amitriptyline/Amitriptylinum tabl., alendro-
nate sodium/Ostenil tabl., nicergoline/Niglostin tabl., 
and ticlopidine/Apo-Clodin tabl. was observed and it 
suggested that these non-antibiotics were substrates of 
efflux pumps in Enterobacteriaceae and non-fermen-
tative Gram-negative rods (Laudy et al., 2017). For 
amitriptyline/Amitriptylinum tabl. and alendronate 
sodium/Ostenil tabl., significant decreases (≥ 4-fold) 
in the MIC values of these non-antibiotics in the pres-
ence of PAβN were demonstrated for most of K. pneu­
moniae, E. coli, P. aeruginosa, and A. baumannii (only 
for amitriptyline/Amitriptylinum tabl.) clinical strains. 
Similarly, this phenomenon has been observed for 
K. pneumoniae, E. coli, A. baumannii, and S. maltophilia 
strains when ticlopidine/Apo-Clodin tabl were used. 
However, significant decreases in the MIC values of 
nicergoline/Niglostin tabl. were only shown for strains 
of A. baumannii.
An interesting observation was made for ticlo-
pidine. This agent inhibits cellular teichoic acid syn-
thesis and blocks the activity of penicillin-binding 
proteins, which results in the susceptibility of methi-
cillin-resistant S. aureus strains to β-lactams (Farha 
et al., 2013). Ticlopidine does not possess antibacterial 
activity but displays potential synergistic activity with 
cefuroxime against Gram-positive cocci (Farha et al., 
2013). A  particularly important observation was the 
restoration of susceptibility to ticlopidine/Apo-clodin 
tabl. in the presence of PAβN among clinical strains of 
E. coli, K. pneumoniae, A. baumannii, and S. maltophilia 
(Laudy et al., 2017), indicating a different mechanism 
of ticlopidine action against Gram-negative rods com-
pared with Gram-positive bacteria.
The presence of MDR pumps could be an impor-
tant factor that contributes to lack of or poor activity 
of some non-antibiotics against Gram-negative rods.
Interactions between non-antibiotics
and MDR efflux pumps
An important and interesting issue is the influ-
ence of non-antibiotic medicinal products on effi-
cient treatment of bacterial infections in the context 
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of drug interactions with bacterial MDR efflux pumps. 
As early as the 1980s, the influence of salicylates (e.g. 
sodium salicylate and acetylsalicylic acid) on the 
induction of resistance to chloramphenicol, nalidixic 
acid, tetracycline, ampicillin, and cephalosporins was 
demonstrated with reference E. coli strains K-12 
and JF568 (Rosner, 1985; Foulds et al., 1989). Since 
then, the salicylate-associated increase in antibiotic 
resistance has also been described for other Gram- 
negative rods, including K. pneumoniae (Domenio 
et al., 1990), S. enterica subsp. enterica serotype Typhi-
murium (Hartog et al., 2010), and B. ceno ce pa cia 
(Nair et al., 2004). Thus, the question arises whe ther 
different groups of non-antibiotics may affect the acti-
vity of bacterial RND efflux systems and thus modify 
the susceptibility of Gram-negative rods to antibiotics.
Among the non-antibiotics, salicylates have been 
thoroughly investigated, including their influence on 
the expression of genes encoding MDR efflux pumps 
and the change of bacterial sensitivity to antibiotics. 
Acetylsalicylic acid in humans is rapidly hydrolysed 
to salicylic acid in the stomach and liver (Needs and 
Brooks 1985).
The salicylate-induced antibiotic resistance in E. coli 
is due to the increase of transcription level of the mar­
RAB operon, which encodes the MarA protein (Cohen 
et al., 1993). This increased production of the global 
regulator MarA enhances the transcription of the acrAB 
operon. Consequently, this leads to overexpression of 
the multidrug AcrAB-TolC efflux system. Substrates 
for this efflux system include quinolones, tetracycli-
nes, chloramphenicol, tigecycline, rifampicin, fusidic 
acid, oxazolidinones, macrolides, and some β-lactams 
(Laudy, 2008; Nikaido et al., 2012; Li et al., 2015). Sali-
cylate can also affect the other two MDR efflux pumps 
of E. coli, EmrKY (Tanabe et al., 1997; Price et al., 2000) 
and EmrAB (Lomovskaya et al., 1995; Price et al., 2000). 
The ability to extrude tetracycline with the EmrKY 
efflux pump and nalidixic acid with the EmrAB-TolC 
efflux system has been demonstrated.
Importantly, induction of marRAB operon expres-
sion by salicylate is concentration-dependent (Cohen 
et al., 1993). Salicylate at a concentration in the range of 
0.01–0.1 mM, did not induce the mar promoter; how-
ever, at salicylate concentrations above 0.5 mM, the 
expression of marRAB was demonstrated (Cohen et al., 
1993). It was assumed that a therapeutic level of salicy-
late was up to 1.8 mM in the plasma (Wang et al., 2003); 
and thus, at the concentration of 5 mM the observed 
salicylate-induced E. coli antibiotic resistance had 
limited therapeutic value (Rosner, 1985; Cohen et al., 
1993). The recommended levels of acetylsalicylic acid/
Aspirin tabl. in plasma are in the range of 20–100 mg/l 
(0.1–0.55 mM) for analgesia and 150–300 mg/l (0.83–
1.67 mM) for an anti-inflammatory effect. However, 
acetylsalicylic acid at a concentration of 2 mM is recom-
mended to cure chronic inflammatory diseases, such as 
rheumatoid arthritis (Axon and Huskisson, 1992). It 
seemed that acetylsalicylic acid and salicylate only at 
concentrations of 5 mM or higher were toxic to humans 
(Frantz and O’Neill, 1995; Wu, 2000), but it has recently 
been shown that salicylate plasma levels higher than 
2.2 mM are potentially toxic for patients chronically 
treated with salicylate (Wang et al., 2003).
In contrast to the results obtained for S. enterica 
subsp. enterica serotype Typhimurium and E. coli, sali-
cylate showed no significant impact on the expression 
of the operons adeFGH and adeIJK (encoding AdeFGH 
and AdeIJK efflux pumps, respectively, both from the 
RND family) in A. baumannii (Bazyleu and Kumar, 
2014) and the emrRCABsm operon, encoding the 
EmrCABsm efflux pump belonging to the MFS family 
in S. maltophilia (Huang et al., 2013). Moreover, expres-
sion of the adeABC operon, which encodes the AdeABC 
RND efflux pump in A. baumannii, at a high concentra-
tions of salicylate (2.5–4 mM), was reduced 2.5-fold and 
did not show in the case of this strain the influence on 
the susceptibility level of ciprofloxacin, gentamicin, and 
ceftriaxone (Bazyleu and Kumar, 2014).
Recently, the influence of medicinal products con-
taining non-antibiotics other than salicylates (which 
are likely extruded by efflux pumps), with or without 
PAβN, on the susceptibility of different species of Gram- 
-negative rods to quinolones was investigated. Quinolo-
nes in these studies served as an example of compounds 
actively removed by efflux pumps. The participation of 
efflux pumps in resistance to fluoroquinolones has been 
shown in a variety of Gram-negative rod genera (Laudy, 
2008; Nikaido and Pages, 2012; Adabi et al., 2015). 
There were no effects of medicinal products containing 
the following active substances: alendro niane sodium, 
carboplatin, ticlopidine, nicergoline, amitriptyline, and 
NSAIDs, such as diclofenac, mefenamic acid, ibuprofen, 
and naproxen, for the induction of quinolone resistance 
of Gram-negative rods (P. aeruginosa, S. maltophilia, 
A. baumannii, E. coli, K. pneumoniae, and P. mirabilis) 
(Laudy et al., 2016; 2017). The non-antibiotics, with the 
exception of salicylates, are substrates of MDR efflux 
pumps; however, they do not affect the sensitivity of 
Gram-negative rods and can be used safely in the treat-
ment of bacterial infections.
Summary
Knowledge regarding antimicrobial activity of non- 
antibiotics is still limited. The first publications from 
the 1980s and 1990s concerned only a few active sub-
stances, such as salicylates. Recently, direct antibacterial 
activity of a broad spectrum of non-antibiotics (both 
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active substances and the relevant medical products) 
has been demonstrated in vitro. In addition, the active 
substances of the non-antibiotic group, including 
NSAIDs, anti depressants, antiplatelet drugs, and spe-
cific inhibitors of osteoclast-mediated bone resorption 
were found to be substrates of Gram-negative rod efflux 
pumps. The use of a PAβN pump inhibitor increased 
the sensitivity of clinical strains to the aforementioned 
non-antibiotics. The presence of RND efflux systems 
causes lack or low activity of non-antibiotics against 
Gram-negative rods. Among the non-antibiotics, 
only salicylates can induce the expression of operons 
encoding pump systems and efflux-dependent resist-
ance to antibiotics in E. coli, S. enterica subsp. enterica 
serotype Typhimurium and B. cenocepacia. The notice-
able impact of MDR efflux pumps on the resistance of 
Gram-negative rods to non-antibiotics as well as to clas-
sic antibiotics emphasizes the urgent need to look for 
inhibitors of these pumps that could be used in therapy. 
Despite extensive scientific research, also conducted by 
pharmaceutical companies, an efflux pump inhibitor 
that is not toxic to humans and can be applied in anti-
bacterial therapy has not yet been discovered.
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